+

US20020156126A1 - FT-0554 substance and its production - Google Patents

FT-0554 substance and its production Download PDF

Info

Publication number
US20020156126A1
US20020156126A1 US10/120,523 US12052302A US2002156126A1 US 20020156126 A1 US20020156126 A1 US 20020156126A1 US 12052302 A US12052302 A US 12052302A US 2002156126 A1 US2002156126 A1 US 2002156126A1
Authority
US
United States
Prior art keywords
substance
microorganism
present
medium
cultured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/120,523
Inventor
Satoshi Omura
Kazuro Shiomi
Rokuro Masuma
Yuzuru Iwai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kitasato Institute
Original Assignee
Kitasato Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kitasato Institute filed Critical Kitasato Institute
Priority to US10/120,523 priority Critical patent/US20020156126A1/en
Publication of US20020156126A1 publication Critical patent/US20020156126A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin

Definitions

  • This invention relates to novel FT-0554 substance useful for treatment for infection of parasite, especially helminth, and its production.
  • Anthelmintics used at present such as avermectins, mebendazole and praziquantel, are not always sufficient for satisfactory in usefulness and toxicity, and the anthelmintics, which can solve these problems, are strongly, required.
  • the present invention provides novel FT-0554 substance, which can satisfy the above requirements, and its production.
  • An object of the present invention is to provide FT-0554 substance shown by the compound of the formula [1]
  • Another object of the present invention is to provide a process for production of FT-0554 substance of the formula [1]
  • [0008] which comprises culturing a microorganism belonging to fungus having FT-0554 substance producing activity, accumulating FT-0554 substance in the cultured medium and isolating FT-0554 substance from the cultured medium.
  • FT-0554 substance producing microorganism is the fungi having FT-0554 substance producing activity and is not limited.
  • a microorganism used for production of FT-0554 is a fungus strain FT-0554 isolated from a newly collected sponge by the inventors of the present invention.
  • Taxonomical properties of the microorganism are illustrated as follows.
  • the microorganism of the present invention shows good growth on Czapek-yeast extract agar medium which contains seawater 50% (salt content 3.4%), malt extract agar medium, Czapek-yeast extract agar medium which contains sucrose 20% and potato-glucose agar medium, with abundance of conidia.
  • Plural aspergillae consist of metulae and phialides with the size of 8.4-11.4 ⁇ 2.4-3.4 ⁇ m and 5.4-8.6 ⁇ 2.8-3.3 ⁇ m. respectively.
  • Whole of the vesicles is covered with metulae with forming conidial heads segmented from spherical to cylindrical.
  • Conidia is globose with a size of diameter 3-4.5 ⁇ m having smooth to rough surface.
  • Optimum growth condition of the present strain is pH 5-7, temperature 16-36° C. and seawater concentration 1) 50-100%.
  • Growth range of the strain is pH 3-10, temperature 12-45° C. and seawater concentration 2) 0-100%.
  • the present microorganism strain has deposited as Aspergillus niger FT-0554 FERM P-16399 in National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Science and Technology, 1-3, Higashi 1 - chose, Tsukuba-shi, Ibaraki-ken, Japan on Sep. 1, 1997. Further, the present microorganism strain was transferred to the microorganism deposition under Budapest Treaty in National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Science and Technology, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan on Jul. 31, 1998, and was given deposition No. FERM BP-6443 from the International Deposition Authority.
  • Production of FT-0554 substance of the present invention can be performed by culturing microorganism belonging to fungi having producing activity of FT-0554 substance and isolating from the cultured mass and purifying the product.
  • the microorganism strain used in the present invention can be the above microorganism strain, its variants and mutants, and all strains having FT-0554 substance producing activity belonging to fungi.
  • Nutritional sources for production of the above FT-0554 substance can be a nutritional source for fungi.
  • nitrogen sources are commercially available peptone, meat extract, corn steep liquor, cottonseed powder, peanut powder, soybean flour, yeast extract, NZ-amine, casein hydrolyzate, sodium nitrate, ammonium nitrate and ammonium sulfate.
  • carbon sources are carbohydrate such as glycerin, starch, glucose, galactose and mannose, or carbon source such as fats and oil, and inorganic salts such as sodium chloride, phosphate, calcium carbonate and magnesium sulfate. These can be used with or combination thereof.
  • Trace metallic salt and animal, vegetable or mineral oil as antiform agent can be added if necessary. These are substance, which can be assimilated by the producing strain and are useful for production of FT-0554 substance, can be used. All the known medium for culturing the fungus can be used. Mass production of FT-0554 substance can preferably be performed by a liquid culture. Culturing temperature can be applied within the range of growing the producing microorganism strain and producing FT-0554 substance. Culturing can be performed by selecting suitable conditions depending on the nature of FT-0554 substance producing strain.
  • FT-0554 substance can be extracted by water immiscible organic solvent such as chloroform and ethyl acetate from the culture liquid.
  • water immiscible organic solvent such as chloroform and ethyl acetate
  • known isolation method used for lipophilic substance for example adsorption chromatography, gel filtration chromatography, scratching from thin layer chromatography, centrifugal counter current chromatography, HPLC, and the like with or without combination thereof or repeated operation, can be applied to obtain purified substance.
  • FT-0554 substance is determined as the following chemical structure.
  • FT-0554 substance As shown in the above, physico-chemical properties of FT-0554 substance are explained in detail, however no compound having identical properties have been reported. Consequently, FT-0554 substance is defined as novel substance.
  • NADH-fumarate reductase inhibitory activity of FT-0554 of the present invention is explained as follows.
  • Muscles of Ascaris suum were homogenized in 120 mM sodium phosphate solution (pH 7.0) and centrifuged at 3,000 ⁇ g for 10 minutes to collect the supernatant solution. The supernatant was further centrifuged at 10,000 ⁇ g for 20 minutes to collect the precipitate. The precipitate was suspended in 120 mM sodium phosphate solution (pH 7.0) to obtain mitochondrial fraction.
  • test sample dissolved in 50% dimethyl sulfoxide solution was added into 96 holes microplate, 120 mM sodium phosphate solution (pH 7.0) containing 0.35 mM NADH. 7.2 mM disodium fumarate and 18 mg/ml bovine serum albumin was added thereto, and pre-incubated in the microplate reader ELx808 (Bio-Tek industries Co.) at 37° C. for 5 minutes.
  • Antimicrobial activity of FT-0554 substance of the present invention is as follows.
  • Chloroform solution of the compound of the present invention (1 mg/ml) 10 ⁇ l is dipped on a filter paper disk (Advantec Co. diameter 6 mm). which is air-dried to remove the solvent. The air-dried to remove the solvent. The dried disks are put on the agar plates containing test organisms, incubated at 37° C. or 27° C. for 24 hours, and diameter of the inhibition zone around the paper disk is measured. Result are shown in Table 3.
  • FT-0554 substance of the present invention has weak growth inhibitory activity against some microorganisms.
  • FIG. 1 shows UV spectrum of FT-0554 substance of the present invention in 1-propanol solution (50 ⁇ M).
  • FIG. 2 shows IR spectrum of FT-0554 substance of the present invention (KBr Tab.).
  • a loopful of Aspergillus niger FT-0554 (FERM BP-6443) cultured in agar slant medium was inoculated into the liquid medium (pH 7.0) containing glucose 2.0%, polypeptone (Nihon Seiyaku Co.) 0.5%, agar 0.1%, yeast extract (Oriental Yeast Co.) 0.2%, magnesium sulfate 7 hydrate 0.05% and pottassium dihydrogen phosphate 0.1% dissolved in 50% natural seawater (salt concentration 3.4% natural seawater was used) and divided into 100 ml in a 500 ml Erlenmeyer flask, and shake cultured at 27° C. for 2 days.
  • This seed culture liquid each 1 ml was inoculated into the liquid medium containing potato dextrose broth (Difco Inc.) 2.4% dissolved in 50% natural seawater (salt concentration 3.4% natural seawater was used) divided each 100 ml in a 500 ml Erlenmeyer flask ( ⁇ 30 flasks) and shake cultured at 27° C. for 96 hours.
  • potato dextrose broth Difco Inc.
  • 50% natural seawater salt concentration 3.4% natural seawater was used
  • the crude substance II was charged on a silica gel thin layer plates (Merck Art, 5744) and developed with n-hexane-ethyl acetate (1:1). Active fraction was scratched and eluated with chloroform-methanol (2:1). The eluate was concentrated in vacuo to obtain crude substance III, 13.4 mg. Further the substance III was charged on Sephadex LH-20 column and eluated with chloroform-methanol (1:2). The eluate was concentrated in vacuo to obtain FT-0554 substance as white powder 10.0 mg.
  • FT-0554 substance of the present invention is expected to be a satisfactory and useful medicament for treatment of parasitosis.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

The present invention is to obtain novel FT-0554 substance which is useful for treatment of helminthiasis. The present invention comprising the steps of culturing the microorganism belonging to fungi having producing activity of FT-0554 substance represented by the following formula [I]
Figure US20020156126A1-20021024-C00001
subjected to accumulation of FT-0554 substance in the cultured medium, and isolating FT-0554 substance from the said cultured mass. The medicament useful for treatment of parasitic infection, specifically helminthiasis can be obtained.

Description

    FIELD OF THE INVENTION
  • This invention relates to novel FT-0554 substance useful for treatment for infection of parasite, especially helminth, and its production. [0001]
    • PRIOR ARTS
  • Parasitosis is reducing as a result of improvement in sanitary conditions and progress of anthelmintics. Recently, however, the import parasitosis, zoonotic parasitosis, opportunistic parasitosis and parasitosis originated from perishable foods are prevailing and become crucial problems, Further the parasitosis produces large economical burdens in the stock-farming and agriculture. For infection of helminth in the parasite, at present, avermectins, mebendazole, praziquantel, and others are used for treatment of helminth. [0002]
    • PROBLEMS TO BE SOLVED BY THE INVENTION
  • Anthelmintics used at present, such as avermectins, mebendazole and praziquantel, are not always sufficient for satisfactory in usefulness and toxicity, and the anthelmintics, which can solve these problems, are strongly, required. [0003]
  • Consequently, the present invention provides novel FT-0554 substance, which can satisfy the above requirements, and its production. [0004]
    • MEANS FOR SOLVING THE PROBLEMS
  • We have studided NADH-fumarate reductase, which was one of the promising targets against anthelmintics, in the electron transport system of the helminth, and explored for screening in the microbial culture. We have found that novel FT-0554 substance had NADH-fumarate reductase inhibitory activity, and completed the present invention according to this acknowledge. [0005]
  • An object of the present invention is to provide FT-0554 substance shown by the compound of the formula [1] [0006]
    Figure US20020156126A1-20021024-C00002
  • Another object of the present invention is to provide a process for production of FT-0554 substance of the formula [1] [0007]
    Figure US20020156126A1-20021024-C00003
  • which comprises culturing a microorganism belonging to fungus having FT-0554 substance producing activity, accumulating FT-0554 substance in the cultured medium and isolating FT-0554 substance from the cultured medium. [0008]
  • Further object of the present invention is to provide a microorganism belonging to fungi and having FT-0554 substance producing activity of the above process being [0009] Aspergillus niger FT-0554. Still further object of the present invention is to provide a microorganism belonging to fungi and having FT-0554 substance producing activity being Aspergillus niger FT-0554.
  • FT-0554 substance producing microorganism is the fungi having FT-0554 substance producing activity and is not limited. Preferable example of a microorganism used for production of FT-0554 is a fungus strain FT-0554 isolated from a newly collected sponge by the inventors of the present invention. [0010]
  • Taxonomical properties of the microorganism are illustrated as follows. [0011]
  • Taxonomical properties of a strain FT-0554. [0012]
  • (1) Cultured properties on various media [0013]
  • Results of macroscopic observation of the strain of the present microorganism cultured at 25° C. for 7 days are shown in Table 1. [0014]
    TABLE 1
    Growth condition Color of Color of
    on the medium surface of reverse side soluble
    Medium (diameter of colony) colony of colony pigment
    Czapek-yeast good (82 mm) black brown pale yellow none
    extract agar velvety, entire
    Malt extract good (81 mm) black brown pale yellow none
    agar medium velvety, entire
    20% sucrose Czapek-yeast good (82 mm) black brown pale yellow none
    extract agar medium velvety, entire
    Potate-glucose good (>85 mm) black brown pale yellow none
    agar medium velvety, entire
    Miura agar medium moderate (40 mm) black brown white none
    velvety, entire
  • (2) Morphological properties [0015]
  • The microorganism of the present invention shows good growth on Czapek-yeast extract agar medium which contains seawater 50% (salt content 3.4%), malt extract agar medium, Czapek-yeast extract agar medium which contains sucrose 20% and potato-glucose agar medium, with abundance of conidia. [0016]
  • Microscopical observation of colonies grown on Czapek-yeast extract agar medium shows transparent hyphae with septa, straight grown conidiophore on the substrate mycelia with length 500 μm-2.5 mm, and foot-cell in the basement. Tops of conidiophores are hypertrophic from spherical to subspherical with forming vesicles of diameter 35-60 μm. [0017]
  • Plural aspergillae consist of metulae and phialides with the size of 8.4-11.4×2.4-3.4 μm and 5.4-8.6×2.8-3.3 μm. respectively. Whole of the vesicles is covered with metulae with forming conidial heads segmented from spherical to cylindrical. Conidia is globose with a size of diameter 3-4.5 μm having smooth to rough surface. [0018]
  • (3) Physiological properties [0019]
  • 1) Optimum growth condition [0020]
  • Optimum growth condition of the present strain is pH 5-7, temperature 16-36° C. and seawater concentration [0021] 1)50-100%.
  • [0022] 1): salt concentration 3.4% natural seawater is used
  • 2) Growth condition [0023]
  • Growth range of the strain is pH 3-10, temperature 12-45° C. and seawater concentration [0024] 2) 0-100%.
  • [0025] 2): salt concentration 3.4% natural seawater is used
  • 3) Nature [0026]
  • Aerobic [0027]
  • As shown in the above, culture condition, taxonomical properties and physiological properties of the present microorganism strain FT-0554 are compared with the known microorganism strains. The present strain is identified as belonging to [0028] Aspergillus niger and referred to Aspergillus niger FT-0554.
  • The present microorganism strain has deposited as [0029] Aspergillus niger FT-0554 FERM P-16399 in National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Science and Technology, 1-3, Higashi 1 - chose, Tsukuba-shi, Ibaraki-ken, Japan on Sep. 1, 1997. Further, the present microorganism strain was transferred to the microorganism deposition under Budapest Treaty in National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Science and Technology, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan on Jul. 31, 1998, and was given deposition No. FERM BP-6443 from the International Deposition Authority.
  • Production of FT-0554 substance of the present invention can be performed by culturing microorganism belonging to fungi having producing activity of FT-0554 substance and isolating from the cultured mass and purifying the product. The microorganism strain used in the present invention can be the above microorganism strain, its variants and mutants, and all strains having FT-0554 substance producing activity belonging to fungi. [0030]
  • Nutritional sources for production of the above FT-0554 substance can be a nutritional source for fungi. Examples of nitrogen sources are commercially available peptone, meat extract, corn steep liquor, cottonseed powder, peanut powder, soybean flour, yeast extract, NZ-amine, casein hydrolyzate, sodium nitrate, ammonium nitrate and ammonium sulfate. Example of carbon sources are carbohydrate such as glycerin, starch, glucose, galactose and mannose, or carbon source such as fats and oil, and inorganic salts such as sodium chloride, phosphate, calcium carbonate and magnesium sulfate. These can be used with or combination thereof. [0031]
  • Trace metallic salt and animal, vegetable or mineral oil as antiform agent can be added if necessary. These are substance, which can be assimilated by the producing strain and are useful for production of FT-0554 substance, can be used. All the known medium for culturing the fungus can be used. Mass production of FT-0554 substance can preferably be performed by a liquid culture. Culturing temperature can be applied within the range of growing the producing microorganism strain and producing FT-0554 substance. Culturing can be performed by selecting suitable conditions depending on the nature of FT-0554 substance producing strain. [0032]
  • FT-0554 substance can be extracted by water immiscible organic solvent such as chloroform and ethyl acetate from the culture liquid. In addition to the above extraction method, known isolation method used for lipophilic substance, for example adsorption chromatography, gel filtration chromatography, scratching from thin layer chromatography, centrifugal counter current chromatography, HPLC, and the like with or without combination thereof or repeated operation, can be applied to obtain purified substance. [0033]
  • Physico-chemical properties of FT-0554 substance of the present invention are shown as follows. [0034]
  • (1) Nature white powder or amorphous [0035]
  • (2) Molecular weight 361.2374 (M+H, high resolution fast atom bombardment mass spectroscopy) [0036]
  • (3) Molecular formula C[0037] 22H32O4
  • (4) Specific rotation: [a][0038] D 25=+35.83 (c=0.1, 1-propanol)
  • (5) UV absorption maximum (in 1-propanol): As shown in FIG. 1, maximum absorption at 205 nm (shoulder, ε=10800) and 231 nm (ε=21000). [0039]
  • (6) IR absorption maximum (KBr Tab): As shown in FIG. 2, maximum absorption at 3430, 2960, 2920, 2850, 1740, 1660, 1460, 1400, 1380, 1180, 1120 and 1000 cm[0040] −1
  • (7) [0041] 1H-NMR: chemical shift in deuterochloroform (ppm) and spin-spin coupling constant (Hz) in Table 2
  • (8) [0042] 13C NMR: chemical shift in deuterochloroform (ppm) in Table 2
  • (9) Solubility in solvent: soluble in chloroform, ethanol, 1-propanol, toluene and ethyl acetate, insoluble in water and n-hexane [0043]
  • (10) Color reaction: positive for sulfuric acid and iodine. [0044]
    TABLE 2
    13C 1H
    170.6 s
    145.2 d 5.79 dd (1 H, J = 6.9, 15.2)
    138.9 d 5.46 dd (1 H, J = 7.6, 15.2)
    137.9 d 6.37 dd (1 H, J = 10.2, 15.2)
    133.7 s
    127.0 d 5.76 d (1 H, J = 10.9 Hz)
    126.0 d 6.02 dd (1 H, J = 10.2, 15.2)
    124.6 d 6.17 dd (1 H, J = 10.9, 15.2)
    122.0 d 5.48 dd (1 H, J = 7.9, 15.2)
     80.2 d 4.92 d (1 H, J = 7.9)
     68.0 d 4.57 s (1 H)
     58.5 d 3.52 s (1 H)
     58.2 s
     47.2 t 1.96 dd (1 H, J = 7.7, 13.7)
    2.09 dd (1 H, J = 7.1, 13.7)
     38.6 d 2.06 m (1 H)
     34.8 d 2.42 m (1 H)
     29.8 t 1.31 dq (2 H, J = 7.1, 7.3)
     20.2 q 0.98 d (3 H, J = 6.8)
     19.4 q 0.97 d (3 H, J = 6.8)
     17.8 q 1.45 s (3 H)
     16.5 q 1.69 s (3 H)
     11.8 q 0.85 t (3 H, J = 7.3)
  • In Table 2, s: singlet, d: doublet, t: triplet, q: quartet, m: multiplet, H: number of proton, and J: spin-spin coupling constant (Hz). [0045]
  • As a result of detailed examination of physico-chemical properties and spectrum data of FT-0554 substance, FT-0554 substance is determined as the following chemical structure. [0046]
    Figure US20020156126A1-20021024-C00004
  • As shown in the above, physico-chemical properties of FT-0554 substance are explained in detail, however no compound having identical properties have been reported. Consequently, FT-0554 substance is defined as novel substance. [0047]
  • NADH-fumarate reductase inhibitory activity of FT-0554 of the present invention is explained as follows. [0048]
  • Muscles of [0049] Ascaris suum were homogenized in 120 mM sodium phosphate solution (pH 7.0) and centrifuged at 3,000×g for 10 minutes to collect the supernatant solution. The supernatant was further centrifuged at 10,000×g for 20 minutes to collect the precipitate. The precipitate was suspended in 120 mM sodium phosphate solution (pH 7.0) to obtain mitochondrial fraction.
  • After 10 μl of test sample dissolved in 50% dimethyl sulfoxide solution was added into 96 holes microplate, 120 mM sodium phosphate solution (pH 7.0) containing 0.35 mM NADH. 7.2 mM disodium fumarate and 18 mg/ml bovine serum albumin was added thereto, and pre-incubated in the microplate reader ELx808 (Bio-Tek industries Co.) at 37° C. for 5 minutes. [0050]
  • Mitochondrial fraction of [0051] Ascaris suum 10 μl (protein content 0.3 mg) was added therein and incubated at 37° C. for 10 minutes. Absorption of NADH at 340 nm was measured every 15 seconds. As a result of quantitative measurement of NADH-fumarate reductase activity shown by decrease in the slope of absorbancy at 340 nm, 50% inhibition of NADH-fumarate reductase activity were obtained at 2.8 μM of FT-0554 substance. Consequently, FT-0554 substance can be expected to use as drug for treatment or prevention of helminthiasis.
  • Antimicrobial activity of FT-0554 substance of the present invention is as follows. [0052]
  • Chloroform solution of the compound of the present invention (1 mg/ml) 10 μl is dipped on a filter paper disk (Advantec Co. diameter 6 mm). which is air-dried to remove the solvent. The air-dried to remove the solvent. The dried disks are put on the agar plates containing test organisms, incubated at 37° C. or 27° C. for 24 hours, and diameter of the inhibition zone around the paper disk is measured. Result are shown in Table 3. [0053]
    TABLE 3
    inhibition zone
    Test organisms diameter (mm)
    Escherichia coli KB213 (NIHJ) −
    Escherichia coli KB176 (NIHJ JC-2, IFO 12734) −
    Pseudomonas aeruginosa P-3 KB105 +
    Xanthomonas oryzae KB88 −
    Micrococcus luteus KB40 (PCI 1001) −
    Staphylococcus aureus KB210 −
    Mycobacterium smegmatis KB42 (ATCC 607) −
    Bacillus subtilis KB27 (PCI 219) −
    Bacteroides fragilis KB169 (ATCC 23745) −
    Acholeplasma laidrawii KB174 −
    Candida albicans KF1 12
    Saccharomyces cervisiae KF26 −
    Aspergillus niger KF103 (ATCC 6275) −
    Pyricularia oryzae KF180 ±
    Mucor racemosus KF223 (IFO 4581) 10
  • As shown in Table 3, FT-0554 substance of the present invention has weak growth inhibitory activity against some microorganisms.[0054]
    • BRIEF EXPLANATION OF THE DRAWINGS
  • FIG. 1 shows UV spectrum of FT-0554 substance of the present invention in 1-propanol solution (50 μM). [0055]
  • FIG. 2 shows IR spectrum of FT-0554 substance of the present invention (KBr Tab.).[0056]
    • EMBODIMENTS OF THE PRESENT INVENTION
  • The following examples illustrate the present invention, but is not construed to limit the invention. [0057]
    • EXAMPLE
  • A loopful of [0058] Aspergillus niger FT-0554 (FERM BP-6443) cultured in agar slant medium was inoculated into the liquid medium (pH 7.0) containing glucose 2.0%, polypeptone (Nihon Seiyaku Co.) 0.5%, agar 0.1%, yeast extract (Oriental Yeast Co.) 0.2%, magnesium sulfate 7 hydrate 0.05% and pottassium dihydrogen phosphate 0.1% dissolved in 50% natural seawater (salt concentration 3.4% natural seawater was used) and divided into 100 ml in a 500 ml Erlenmeyer flask, and shake cultured at 27° C. for 2 days.
  • This seed culture liquid each 1 ml was inoculated into the liquid medium containing potato dextrose broth (Difco Inc.) 2.4% dissolved in 50% natural seawater (salt concentration 3.4% natural seawater was used) divided each 100 ml in a 500 ml Erlenmeyer flask (×30 flasks) and shake cultured at 27° C. for 96 hours. [0059]
  • Cultured liquid medium was centrifuged and obtained mycelia was extracted with ethanol 3 lit. Ethanol was removed in vacuo. Mycelia was again extracted with n-hexane and concentrated in vacuo to obtain crude substance I, 1.9 g. This was charged on the column of silica gel (95 g, Merck Art. 7734) packed with n-hexane, washed with mixture of n-hexane-ethyl acetate (10:1), and eluated with n-hexane-ethyl acetate (10:2). The eluate was concentrated in vacuo to obtain crude substance II, 22.7 mg. The crude substance II was charged on a silica gel thin layer plates (Merck Art, 5744) and developed with n-hexane-ethyl acetate (1:1). Active fraction was scratched and eluated with chloroform-methanol (2:1). The eluate was concentrated in vacuo to obtain crude substance III, 13.4 mg. Further the substance III was charged on Sephadex LH-20 column and eluated with chloroform-methanol (1:2). The eluate was concentrated in vacuo to obtain FT-0554 substance as white powder 10.0 mg. [0060]
    • EFFECT OF THE INVENTION
  • As explained hereinabove, FT-0554 substance of the present invention is expected to be a satisfactory and useful medicament for treatment of parasitosis. [0061]

Claims (12)

1. A process for producing FT-0554 substance of formula [1]
Figure US20020156126A1-20021024-C00005
comprising culturing a microrganism belonging to fungi having activity for producing FT-0554 substance in a medium, accumulating FT-0554 substance in the cultured medium and isolating FT-0554 substance from said culture.
2. The process according to claim 1, wherein said microorganism is Aspergillus niger FT-0554.
3. The process according to claim 1, wherein said microorganism is Aspergillus niger FT-0554 FERM BP-6443.
4. The process according to claim 1, wherein said microorganism is cultured at a ph of 3-10 and a temperature of 12-45° C.
5. The process according to claim 1, wherein said microorganism is cultured at a ph of 5-7 and a temperature of 16-36° C.
6. The process according to claim 1, wherein said medium is a liquid.
7. The process according to claim 1, wherein said medium contains seawater.
8. The process according to claim 1, wherein said microorganism is cultured at a ph of 3-10, a temperature of 12-45° C. and in a medium comprising 50-100% seawater.
9. A microorganism belonging to fungi and having the ability to produce FT-0554.
10. The microorganism according to claim 9, wherein said microorganism is Aspergillus niger FT-0554.
11. The microorganism according to claim 9, wherein said microorganism is Aspergillus niger FT-0554 FERM BP-6443.
12. A biologically pure culture of Aspergillus niger FT-0554 FERM BP-6443.
US10/120,523 1997-11-11 2002-04-12 FT-0554 substance and its production Abandoned US20020156126A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/120,523 US20020156126A1 (en) 1997-11-11 2002-04-12 FT-0554 substance and its production

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP9-308222 1997-11-11
JP30822297 1997-11-11
US09/509,770 US6486197B1 (en) 1997-11-11 1998-09-17 Substance ft-0554 and process for producing the same
US10/120,523 US20020156126A1 (en) 1997-11-11 2002-04-12 FT-0554 substance and its production

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US09/509,770 Division US6486197B1 (en) 1997-11-11 1998-09-17 Substance ft-0554 and process for producing the same
PCT/JP1998/004178 Division WO1999024439A1 (en) 1997-11-11 1998-09-17 Novel substance ft-0554 and process for producing the same

Publications (1)

Publication Number Publication Date
US20020156126A1 true US20020156126A1 (en) 2002-10-24

Family

ID=17978403

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/509,770 Expired - Fee Related US6486197B1 (en) 1997-11-11 1998-09-17 Substance ft-0554 and process for producing the same
US10/120,523 Abandoned US20020156126A1 (en) 1997-11-11 2002-04-12 FT-0554 substance and its production

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/509,770 Expired - Fee Related US6486197B1 (en) 1997-11-11 1998-09-17 Substance ft-0554 and process for producing the same

Country Status (16)

Country Link
US (2) US6486197B1 (en)
EP (1) EP1033370B1 (en)
JP (1) JP4380913B2 (en)
CN (1) CN1100781C (en)
AR (1) AR018512A1 (en)
AT (1) ATE266665T1 (en)
AU (1) AU9094998A (en)
BR (1) BR9813933A (en)
DE (1) DE69823866T2 (en)
DK (1) DK1033370T3 (en)
ES (1) ES2221194T3 (en)
HK (1) HK1026703A1 (en)
PT (1) PT1033370E (en)
TW (1) TW526201B (en)
WO (1) WO1999024439A1 (en)
ZA (1) ZA988803B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60033197T2 (en) * 2000-08-22 2007-11-08 The Kitasato Institute NEW FT-0554A COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
WO2003048373A1 (en) * 2001-12-04 2003-06-12 The Kitasato Institute Novel substance fki-0550 and process for producing the same
AU2002216364A1 (en) * 2001-12-11 2003-06-23 The Kitasato Institute Novel substance fki-1083 and process for producing the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU717878B2 (en) 1996-03-06 2000-04-06 Tsumura & Co. Novel iridoid derivatives and a vascularization inhibitor having for its active ingredient said derivative

Also Published As

Publication number Publication date
ZA988803B (en) 1999-04-15
JP4380913B2 (en) 2009-12-09
AR018512A1 (en) 2001-11-28
TW526201B (en) 2003-04-01
CN1278824A (en) 2001-01-03
US6486197B1 (en) 2002-11-26
DK1033370T3 (en) 2004-09-20
EP1033370A1 (en) 2000-09-06
EP1033370B1 (en) 2004-05-12
BR9813933A (en) 2000-09-19
AU9094998A (en) 1999-05-31
CN1100781C (en) 2003-02-05
WO1999024439A1 (en) 1999-05-20
EP1033370A4 (en) 2001-08-08
ATE266665T1 (en) 2004-05-15
HK1026703A1 (en) 2000-12-22
DE69823866T2 (en) 2005-05-19
ES2221194T3 (en) 2004-12-16
DE69823866D1 (en) 2004-06-17
PT1033370E (en) 2004-08-31

Similar Documents

Publication Publication Date Title
EP0271581A1 (en) Novel compounds dc-88a and dc-89a1 and process for their preparation
US6306629B1 (en) Microorganism streptomyces exfoliatus yj-118 and a method for producing pravastatin sodium by using the strain
Uchida et al. Kurasoins A and B, New Protein Farnesyltransferase Inhibitors Produced by Paecilomyces sp. FO-3684 I. Producing Strain, Fermentation, Isolation, and Biological Activities
HU182267B (en) Process for preparing the antibiotic c-15003 p-3
US6486197B1 (en) Substance ft-0554 and process for producing the same
US4575489A (en) Streptomyces albulus subsp. ochragerus subsp. nov. culture for making peptide
Shibazaki et al. YM-47522, a novel antifungal antibiotic produced by Bacillus sp. I. Taxonomy, fermentation, isolation and biological properties
DK143570B (en) METHOD OF PREPARING MAYTANSINOL MAYTANACIN AND OR MAYTANSINOL PROPIONATE
EP1454905B1 (en) Novel substance fki-1083 and process for producing the same
US4940582A (en) Antibiotic YI-HU3
US5233062A (en) Antibiotic eicosenoic acids
US7982057B2 (en) Compound of stemphones and production thereof
US7794991B2 (en) Stemphones and production thereof
JPH06234784A (en) New antibiotic sf 2768 substance and its production
JPH05155877A (en) Novel substances: urauchimycin a and urauchimycin b and production thereof
US4339535A (en) Process for preparing antibiotic EM 4940
JP3530563B2 (en) KO-8119 substance and process for producing the same
US4612285A (en) Novel antitumor antibiotic awamycin and its production
US5232943A (en) Antibiotics mer-af1032a and mer-af1032b
KR0184752B1 (en) A novel macrolide antibiotics and micro-organism producing it
JPH0856688A (en) Substance fo-2546 and its production
JPS6348284A (en) Novel antibiotic yp-02908l-a and production thereof
JPH06116281A (en) Xanthoquinodin a, b, c, d and/or e substances and their production
WO2003048373A1 (en) Novel substance fki-0550 and process for producing the same
JPH0565297A (en) Enopeptin A, method for producing the same, and antiviral agent

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载